Answers are grounded in this paper and cite their sources.
Clinical commentary examines strategies to enhance nintedanib persistence in fibrosing interstitial lung disease, suggesting tailored dosing maintains efficacy.
Francesco Bonella, Sebastian Majewski; How to improve treatment persistence in fibrosing ILD patients on nintedanib, without sacrificing effectiveness? A p
No takes yet. Share an insight, caveat, or question.
Bonella et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: